Humanin

Humanin is a mitochondrial-derived peptide with demonstrated therapeutic potential for multiple age-related conditions.¹ In preclinical models, humanin has shown neuroprotective effects and cognitive benefits, reducing amyloid-beta accumulation and improving cognitive deficits in Alzheimer's disease models, with stroke studies demonstrating up to 50% reduction in infarct volume when administered before or shortly after cerebral artery occlusion.² Cardiovascular applications include reversal of cardiomyocyte apoptosis, reduction of cardiac fibrosis, and preservation of cardiac function following myocardial infarction through antioxidant mechanisms and inhibition of apoptosis pathways.¹ Metabolic benefits documented in animal studies include improved glucose metabolism and insulin sensitivity, reduced visceral adiposity with increased lean body mass, and favorable changes in circulating metabolic markers including decreased IGF-I levels and triglycerides.³ Additionally, humanin demonstrates protective effects against oxidative stress and inflammatory conditions, with potential applications in neurodegenerative diseases, autoimmune disorders, and age-related metabolic dysfunction including diabetes and obesity.¹

Reported side effects of Humanin include mild and short-lived injection or infusion site reactions such as redness, swelling, and skin irritation, as well as rare gastrointestinal symptoms like nausea, vomiting, and mild diarrhea typically limited to the first dose.⁴,⁵ Safety data is limited, primarily from preclinical cell culture and animal studies, with no major toxicity observed at therapeutic doses and excellent tolerance noted across administration routes, though human clinical trials are lacking.⁵,⁶ Key concerns involve theoretical risks of promoting tumor progression or cellular survival in malignancies, particularly breast and prostate cancers, based on rodent models where Humanin facilitated tumor growth and chemoresistance, necessitating caution or avoidance in patients with active cancer or history of malignancy.⁴,⁵,⁶,⁷ Potential drug interactions include enhanced insulin sensitivity leading to hypoglycemia, requiring glucose monitoring in diabetic patients, alongside contraindications for known hypersensitivity, severe/unstable diabetes, pregnancy, and breastfeeding due to insufficient data.⁶ Humanin may mitigate chemotherapy side effects like neuropathy, cardiomyopathy, and infertility in preclinical contexts without inducing cancer itself in some models.³,⁵,⁸

Humanin acts primarily by binding to proapoptotic proteins such as Bax, Bim, and tBid, preventing their translocation into mitochondria, suppressing cytochrome C release, and thereby inhibiting mitochondria-dependent apoptosis.¹,⁹,¹⁰ Extracellularly, it binds to receptors including the FPRL1 formyl peptide receptor-like 1 and the CNTFRα/gp130/WSX-1 trimeric complex, activating cytoprotective signaling pathways like PI3K/AKT, JAK2/STAT3, and ERK1/2 while inhibiting JNK/p38 MAPK.¹,⁹,¹⁰,¹¹ Intracellularly, it protects mitochondrial function by reducing reactive oxygen species production via inhibition of electron transport chain complexes I and III, activating the Keap1/Nrf2 antioxidant pathway, and stimulating chaperone-mediated autophagy (CMA) for degradation of oxidized proteins.¹,⁹ These mechanisms collectively confer cytoprotective effects against oxidative stress and cell death.⁹,¹²